Treating Triple Negative Breast Cancer

SLU ID 21-011 | GPER-PROTAC

Background

Triple negative breast cancer is a subtype that is highly aggressive. It has poor survival rates, primarily because there is a lack of molecular targets.

Overview

Researchers at Saint Louis University at the University of Iowa have identified small molecule therapeutics that demonstrate promise in treating triple negative breast cancer without inducing potential drug resistance. The molecules may also be useful for treating a variety of other cancers.

Benefits

The potential benefits this technology include:

• Increasing the survival rate of patients

• Increasing the efficacy of treatments

• Increasing the number of treatment options

• Minimizing the potential for drug resistance

Applications

Potential applications of this technology include:

• Treating triple negative breast cancer

• Treating endocrine-resistant cancer

• Treating ovarian cancer

• Treating endometrial cancer

• Treating prostate cancer

• Treating colon cancer

Opportunity

Saint Louis University and the University of Iowa are seeking partners to further develop and commercialize this technology.